Preliminary ORR 24% for Oncosec's Tavo plus Keytruda in Phase II for melanoma

OncoSec Medical Inc. (NASDAQ:ONCS) reported preliminary data from 21 evaluable metastatic/recurrent melanoma patients in the Phase IIb KEYNOTE-695 trial showing that Tavo tavokinogene telseplasmid/IL-12 plus Keytruda pembrolizumab from Merck & Co. Inc. (NYSE:MRK) led to an observed overall response rate (ORR) of 24%.

This year, OncoSec expects to complete enrollment of about 100 patients refractory to anti-PD-1 mAbs. The The open-label, international trial's primary endpoint is a 20% ORR...